We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00796874
Recruitment Status : Withdrawn (PI decided to terminate study.)
First Posted : November 24, 2008
Last Update Posted : July 25, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:

RATIONALE: Sometimes prostate cancer may not need treatment until it progresses. In this case, active surveillance may be sufficient. Diagnostic procedures, such as magnetic resonance imaging, may be a less invasive method of finding prostate cancer that has progressed.

PURPOSE: This clinical trial is studying how well magnetic resonance imaging works in detecting cancer progression in patients with early-stage prostate cancer who are undergoing active surveillance.

Condition or disease Intervention/treatment
Prostate Cancer Other: active surveillance Other: imaging biomarker analysis Procedure: biopsy Procedure: dynamic contrast-enhanced magnetic resonance imaging Procedure: magnetic resonance imaging Procedure: magnetic resonance spectroscopic imaging

Detailed Description:



  • To determine if MRI parameters (initial volume, number and location of image abnormalities, and MR spectroscopy) can improve the ability to stratify cancer progression risk in patients undergoing active surveillance for early-stage prostate cancer.


  • Determine if changes in non-invasive MRI, validated by MRI-guided biopsies, can accurately detect progression of prostate cancer.

OUTLINE: Patients undergo prostate MRI scans and MRI-guided biopsies of suspicious lesions at baseline. Patients undergo conventional anatomic imaging followed by research biological imaging tests (e.g., magnetic resonance spectroscopic imaging and/or dynamic contrast-enhanced MRI). MRI are repeated at 6 months, 1 year, and then annually until initiation of definitive therapy or for a total of 5 years.

Tissue biopsy with MRI guidance is done at baseline and annually or as clinically indicated based on change in rectal exam, PSA, or maybe done based on change in MR imaging (i.e., new MR lesion or significant change [> 25% increase] in the size of a MR lesion).

Blood samples are collected at baseline and periodically during study for PSA tests.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: MR Imaging to Stratify Prostate Cancer Progression Risk in Patients on Active Surveillance
Study Start Date : October 2008
Primary Completion Date : July 2013
Study Completion Date : July 2013

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Intervention Details:
    Other: active surveillance
    Correlative Study
    Other: imaging biomarker analysis
    Correlative Study
    Procedure: biopsy
    Tissue Removal
    Procedure: dynamic contrast-enhanced magnetic resonance imaging
    Radiolical Medical Imaging
    Procedure: magnetic resonance imaging
    Radiolical Medical Imaging
    Procedure: magnetic resonance spectroscopic imaging
    Radiolical Medical Imaging

Outcome Measures

Primary Outcome Measures :
  1. Prostate cancer progression measured by MRI while on active surveillance [ Time Frame: at 6 months, 1 year and than annualy for 5 years ]

Secondary Outcome Measures :
  1. Prostate cancer changes by MRI [ Time Frame: At 6months, 1 year and annually for 5 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed prostate cancer
  • Low-risk for progression, as evidenced by all of the following:

    • Tumor stage ≤ T2a
    • PSA ≤ 10 ng/mL
    • Gleason score ≤ 7
  • Patients informed of treatment options and has already chosen to undergo active surveillance

    • No decision to stop active surveillance
  • No node-positive or metastatic disease


  • Willing to undergo MRI
  • Willing to undergo prostate biopsy
  • No contraindications to MRI that include, but not limited to, any of the following:

    • Claustrophobia
    • Anxiety
    • Presence of metal or shrapnel in the body
    • Pacemakers
    • Old tattoos with metal-based dye material
  • No contraindication to prostate biopsy
  • No medical conditions, as deemed by the PI or associates, that would prevent or limit the patient participation on the protocol that include, but not limited to, any of the following:

    • Severe coagulopathy
    • History of severe bleeding
    • Severe coronary artery disease
    • Other comorbid conditions that limit life expectancy to less than 2 years


  • No hormone therapy within the past year
  • No prior pelvic radiotherapy
  • No prior prostate resection including transurethral resection of prostate
  • Concurrent participation in other clinical studies (e.g., vitamin D, selenium) allowed provided active surveillance is continued
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00796874

Sponsors and Collaborators
Roswell Park Cancer Institute
Principal Investigator: Anurag K. Singh, MD Roswell Park Cancer Institute
More Information

Responsible Party: Roswell Park Cancer Institute
ClinicalTrials.gov Identifier: NCT00796874     History of Changes
Other Study ID Numbers: CDR0000618738
RPCI-I-124107 ( Other Identifier: Roswell Park Cancer Institute )
First Posted: November 24, 2008    Key Record Dates
Last Update Posted: July 25, 2013
Last Verified: July 2013

Keywords provided by Roswell Park Cancer Institute:
stage I prostate cancer
stage II prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases